Jennerex completes enrollment in Phase 2b trial of liver cancer drug

The TRAVERSE study is designed to assess the efficacy and safety profile of Pexa-Vec against advanced primary liver cancer in patients failing prior therapy with sorafenib.

The primary objective is to determine the overall survival for patients receiving Pexa-Vec with best supportive care, compared to those receiving best supportive care alone.

The study is being conducted at approximately 40 sites across North America, South Korea, Taiwan, Hong Kong, and Europe.

Jennerex president and chief executive officer Laurent Fischer said TRAVERSE is the largest study to date of Pexa-Vec.

"We would like to thank investigators and patients who participated in the study. We believe that physician and patient interest in this trial validates our novel approach to treating HCC and underscores the need for new treatment options for liver cancer, the third most deadly cancer," Fischer added.

The investigational oncolytic immunotherapy is designed to de-bulk tumours via tumour cell lysis, induce a systemic anti-tumour immune response, and selectively target tumour vasculature resulting in a rapid reduction in tumour blood flow.